{
    "clinical_study": {
        "@rank": "52117", 
        "arm_group": [
            {
                "arm_group_label": "Empegfilgrastim 6 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy"
            }, 
            {
                "arm_group_label": "Empegfilgrastim 7,5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive a single administration of empegfilgrastim at a dose of 7,5 mg subcutaneously, 24 h after the chemotherapy"
            }, 
            {
                "arm_group_label": "Filgrastim", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive filgrastim at a dose of   5 \u03bcg/kg subcutaneously daily (until ANC 10 000/\u03bcL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy"
            }, 
            {
                "arm_group_label": "Placebo \u21161", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive a single administration of placebo \u21161 at a dose of 1 ml subcutaneously, 24 h after the chemotherapy."
            }, 
            {
                "arm_group_label": "Placebo \u21162", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive placebo \u21162 subcutaneously daily (until ANC 10 000/\u03bcL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence\n      of CTCAE grade 3/4 neutropenia after a single administration  of recombinant human pegylated\n      filgrastim empegfilgrastim (Extimia\u00ae)  at a dose of 6 or 7,5 mg versus daily administration\n      of filgrastim  at a dose of 5 \u03bcg/kg/day for neutropenia prophylaxis in breast cancer\n      patients  receiving myelosuppressive chemotherapy.\n\n      The study also includes the following determination of pharmacokinetic parameters after\n      repeated administration of the study drug."
        }, 
        "brief_title": "Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chemotherapy-induced Neutropenia", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neutropenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form;\n\n          -  Histologically verified diagnosis of stage IIb/III/IV breast cancer;\n\n          -  Age of 18-70 years inclusive;\n\n          -  Life expectancy of at least 6 months after  inclusion in the study;\n\n          -  If the patient had received the chemotherapy for breast cancer, it should be finished\n             30 days before the beginning of the study;\n\n          -  ECOG Performance Status of 0- 2, not increasing within during 2 weeks before\n             randomization;\n\n          -  ANC level of 1500/\u03bcL and more at the beginning of the study\n\n          -  Platelet count of 100 000/\u03bcL and more at the beginning of the study\n\n          -  Hemoglobin level of 90 g/l and more\n\n          -  Creatinine level <1.5 mg/dl\n\n          -  Total bilirubin level <1.5 \u00d7 the upper limit of normal (ULN)\n\n          -  ALT and/or AST levels <2.5\u00d7ULN (5\u00d7ULN for patients with liver metastases);\n\n          -  Alkaline phosphatase <5\u00d7ULN;\n\n          -  Left ventricular ejection fraction >50% and more;\n\n          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose\n             of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for\n             epirubicin,if in this study planned 6 cycles of chemotherapy ;\n\n          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose\n             of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for\n             epirubicin,if in this study planned 4 cycles of chemotherapy ;\n\n          -  Ability of the participant to follow the protocol requirements, according to the\n             Investigator's opinion;\n\n          -  Patients of childbearing potential must implement reliable contraceptive measures\n             during the study treatment, starting 4 weeks prior randomization and for 6 months\n             after the last administration of the study drug;\n\n          -  Patients should be able to follow the Protocol procedures (according to\n             Investigator's assessment.\n\n        Exclusion Criteria:\n\n          -  Patient has received two or more chemotherapy regimens for the metastatic breast\n             cancer;\n\n          -  Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin,\n             dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.\n\n          -  Pregnancy or breastfeeding;\n\n          -  Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim\n             administration;\n\n          -  Concomitant radiotherapy (except selective radiotherapy of bone metastases);\n\n          -  Surgery, radiotherapy (except selective radiotherapy of bone metastases),\n             administration of any experimental drugs within 30 days prior randomization;\n\n          -  History of bone marrow/stem cell transplantation;\n\n          -  Conditions limiting the patient's ability to follow the protocol;\n\n          -  CTCAE grade 3-4 neuropathy;\n\n          -  HIV, HCV, HBV, T.Pallidum infection(s);\n\n          -  Acute or active chronic infections;\n\n          -  Severe concurrent diseases (for example, severe arterial hypertension, severe heart\n             failure, and other);\n\n          -  Severe depression, schizophrenia, any other mental disorders;\n\n          -  Obstacles in intravenous administration of study drugs;\n\n          -  Simultaneous participation in other clinical trials, previous participation in other\n             clinical trials within 30 days before entering into the trial, previous participation\n             in the same trial."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104830", 
            "org_study_id": "BCD-017-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo \u21162", 
                "description": "Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.", 
                "intervention_name": "empegfilrastim 6 mg", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Extimia", 
                    "metpegfilgrastim", 
                    "pegylated filgrastim", 
                    "peg-GCSF"
                ]
            }, 
            {
                "arm_group_label": "Placebo \u21161", 
                "description": "Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological", 
                "other_name": "GCSF"
            }, 
            {
                "arm_group_label": "Filgrastim", 
                "intervention_name": "Placebo \u21161", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Empegfilgrastim 6 mg", 
                    "Empegfilgrastim 7,5 mg"
                ], 
                "intervention_name": "Placebo \u21162", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo \u21162", 
                "description": "Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.", 
                "intervention_name": "empegfilrastim 7,5 mg", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Extimia", 
                    "metpegfilgrastim", 
                    "pegylated filgrastim", 
                    "peg-GCSF"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "empegfilgrastim", 
            "pegylated filgrastim", 
            "neutropenia", 
            "febrile neutropenia", 
            "chemotherapy-associated neutropenia", 
            "breast cancer", 
            "docetaxel", 
            "doxorubicin"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560027"
                    }, 
                    "name": "HCG Bangalore Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560054"
                    }, 
                    "name": "M.S.Ramaiah Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India"
                    }, 
                    "name": "M.S.Ramaiah Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arkhangelsk", 
                        "country": "Russian Federation", 
                        "zip": "163045"
                    }, 
                    "name": "Arkhangelsk District Clinical Oncology Dispensary"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Clinical Hospital at Chelyabinsk Railway Station"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Engels", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State public health institution \"Regional Oncology Dispensary \u21161\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kazan", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State public health institution \"Republican Clinical Oncology Dispensary\" of the Ministry of Health of the Republic of Tatarstan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnodar", 
                        "country": "Russian Federation", 
                        "zip": "350040"
                    }, 
                    "name": "Clinical Oncology Dispensary N1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Health Care Institution \"Moscow City Oncology Hospital \u2116 62\" Moscow Health Department"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Non-governmental healthcare institution \"Central Clinical Hospital \u2116 2 Semashko\" JSC \"Russian Railways\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nizhny Novgorod", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State public health institution \"Nizhny Novgorod Regional Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State budget healthcare institution Omsk region \"Clinical Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orenburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Health Care Institution \"Orenburg Regional Clinical Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perm", 
                        "country": "Russian Federation", 
                        "zip": "614066"
                    }, 
                    "name": "Perm Region Oncology Dispensary"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pyatigorsk", 
                        "country": "Russian Federation", 
                        "zip": "357502"
                    }, 
                    "name": "Pyatigorsk Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saransk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Federal State Educational Institution of Higher Professional Education \"Mordovia State University N.P. Ogareva \""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sochi", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Health Care Institution \"Oncologic Dispensary \u2116 2\" Health Department of Krasnodar Area"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }, 
                    "name": "N.N.Petrov Oncology Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Military Medical Academy named after S.M. Kirov"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tula", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Budget Institution health care \"Tula Regional Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulyanovsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State public health institution \"Regional Clinical Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation", 
                        "zip": "404130"
                    }, 
                    "name": "Volgograd Regional Oncology Dispensary \u21163"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State Health Care Institution \"Volgograd Regional Clinical Oncology Dispensary \u2116 1\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voronezh", 
                        "country": "Russian Federation"
                    }, 
                    "name": "State public health institution \"Voronezh Regional Clinical Oncology Dispensary\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk City Oncology Dispensary"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk Regional Antitumor Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Kharkiv Regional Clinical Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uzhhorod", 
                        "country": "Ukraine"
                    }, 
                    "name": "Zakarpatskyi Regional Clinical Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsia", 
                        "country": "Ukraine"
                    }, 
                    "name": "Vinnytsia Regional Clinical Oncology Dispensary"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "India", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "International Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia\u00ae Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy", 
        "overall_official": [
            {
                "affiliation": "Biocad", 
                "last_name": "Roman Ivanov, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Federal State Institution \"Moscow Research Oncological Institute P.A.Gertsena \"of the Ministry of Health of the Russian Federation", 
                "last_name": "Larisa Bolotina, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Regional Oncology Dispensary \u21161", 
                "last_name": "Olga Brichkova, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health Arkhangelsk region \"Arkhangelsk Clinical Oncology Dispensary\"", 
                "last_name": "Olga Burdaeva, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Non-governmental healthcare institution \"Central Clinical Hospital \u2116 2 Semashko\" JSC \"Russian Railways\"", 
                "last_name": "Byakhov Michael, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health Stavropol area \"Piatigorsky Oncology Dispensary\"", 
                "last_name": "Vladimir Vladimirov, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State budget healthcare institution Omsk region \"Clinical Oncology Dispensary\"", 
                "last_name": "Rinat Galiulin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health \"Chelyabinsk Regional Clinical Oncology Dispensary\"", 
                "last_name": "Oleg Gladkov, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health \"Clinical Oncology Dispensary \u2116 1\" of the Ministry of Health of the Krasnodar area", 
                "last_name": "Irina Davydenko, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Voronezh Regional Clinical Oncology Dispensary\"", 
                "last_name": "Victoria Elkova, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Kursk Regional Oncology Dispensary\"", 
                "last_name": "Igor Lifirenko, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health \"Volgograd regional oncologic dispensary \u2116 3\"", 
                "last_name": "Nadezhda Kovalenko, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health \"Samara Regional Clinical Oncology Dispensary\"", 
                "last_name": "Michael Kopp, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Military Medical Academy named after S.M. Kirov", 
                "last_name": "Bogdan Kotiv, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution of Health Stavropol area \"Stavropol Regional Clinical Oncology Dispensary\"", 
                "last_name": "Natalia Levchenko, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Nizhny Novgorod Regional Oncology Dispensary\"", 
                "last_name": "Marina Matrosova, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Republican Clinical Oncology Dispensary\" of the Ministry of Health of the Republic of Tatarstan", 
                "last_name": "Guzel Mukhametshina, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State public health institution \"Regional Clinical Oncology Dispensary\"", 
                "last_name": "Sergei Panchenko, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Regional State Health Care Institution \"Orlovsky Oncology Dispensary\"", 
                "last_name": "Alexander Pecheny, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Budget Institution health care \"Tula Regional Oncology Dispensary\"", 
                "last_name": "Igor Pimenov, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution of Tyumen Region \"Regional Oncological Dispensary\"", 
                "last_name": "Andrei Sinykov, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Federal State Educational Institution of Higher Professional Education \"Mordovia State University N.P. Ogareva \"", 
                "last_name": "Pavel Skopin, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution \"Moscow City Oncology Hospital \u2116 62\" Moscow Health Department", 
                "last_name": "Daniil Stroyakovsky", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "\"Russian Oncological Scientific Center N.N.Blokhin\" Russian Academy of Sciences", 
                "last_name": "Sergei Tyulyandin, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution  \"Oncologic Dispensary \u2116 2\" Health Department of Krasnodar Area", 
                "last_name": "Dmitriy Udovica, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution \"Perm Regional Oncology Dispensary\"", 
                "last_name": "Andrei Horinko, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "N.N. Petrov Oncology Research Center of the Ministry of Health of the Russian Federation", 
                "last_name": "Petr Krivorotko, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Non-governmental healthcare institution \"Chelyabinsk Road Clinical Hospital\" JSC \"Russian Railways\"", 
                "last_name": "Yulia Shapovalova, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution \"Volgograd Regional Clinical Oncology Dispensary \u2116 1\"", 
                "last_name": "Ludmila Sheveleva, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Health Care Institution \"Orenburg Regional Clinical Oncology Dispensary\"", 
                "last_name": "Vadim Shirinkin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bangalore Institute of Oncology", 
                "last_name": "Shekar Patil, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mazumdar Shaw Cancer Center and Narayana Hrudayalaya Multispecialty Hosptial", 
                "last_name": "Prasad Narayanan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "M.S.Ramaiah Memorial Hospital", 
                "last_name": "Nalini Kilara, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Donetsk City Municipal Oncology Dispensary", 
                "last_name": "Sergei Kulik, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Donetsk Regional oncology centers", 
                "last_name": "Igor Sedakov, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Zakarpatskii Regional Clinical Oncology Dispensary", 
                "last_name": "Andrei Rusin, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kharkiv Regional Clinical Oncology Center", 
                "last_name": "Yuri Vinnik, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vinnitskii Regional Oncology Dispensary", 
                "last_name": "Sergei Odarchenko, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia\u00ae versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).", 
            "measure": "Duration of  neutropenia CTCAE grade 4", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The duration of grade 4 neutropenia from the 2nd to 4th cycles;", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The incidence of severe neutropenia (grade 3-4)", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Biocad", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocad", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}